Importantly, the rarity of genetic mutations in the DREAM complex [92] raises the value of targeting this complex as a cancer therapy option, in contrast to tumor suppressors like p53, PTEN, and RB, which are frequently mutated and thus challenging to target effectively [96]. Here, KCNIP3 is linked to cancer.